Vexev

Vexev develops automated vascular imaging technology that combines custom robotics designed and manufactured in-house, machine learning, proprietary ultrasound signal processing and analysis, and computational fluid dynamics for vascular systems. Its stated aim is to produce vascular imaging that avoids ionising radiation and reduces operator variation, and to support clinical decision-making with imaging-derived insights.

The company's product is the VxWave Ultrasound Imaging System, an autonomous/semi-autonomous ultrasound system that allows non-specialists to perform vascular ultrasound scans on the upper limb. Vexev describes itself as working in robotic tomographic ultrasound and positions the system for vascular access management, including mapping for arteriovenous fistula creation in patients requiring dialysis. The company also frames its technology as supporting a shift from reactive to proactive care pathways.

Business model

Vexev develops and commercializes a robotic ultrasound imaging system (VxWave) for use in clinical settings, working with dialysis service providers as deployment partners.

Traction

In November 2024 Vexev partnered with U.S. Renal Care, described as the third-largest dialysis provider in the USA, and began enrolment in the CANSCAN clinical trial. Enrolment of 120 patients with chronic kidney disease was completed in July 2025. In November 2025 the company reported that VxWave met clinical endpoints in CANSCAN, with a 94% scanning success rate and a 100% data adequacy rate for vascular access creation strategies at U.S. Renal Care dialysis clinics. Vexev also published research in the Journal of Vascular Access in November 2023.

Latest developments

Vexev reported raising $6M to accelerate U.S. commercialization of its autonomous vascular imaging platform, following the U.S. clinical study results and to advance FDA regulatory activities for VxWave.